The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
The purpose of this multi-center international trial is to evaluate the safety and
 effectiveness of adding iloprost or placebo (an inactive substance that contains no active
 study drug) to sildenafil therapy for pulmonary arterial hypertension (PAH). The study will
 also examine whether patients on sildenafil can reduce the number of iloprost inhalations
 from the approved 6 doses per day to 4 doses per day.
Inclusion Criteria:

 -  Aged 12-85 years; of either gender.

 -  Confirmed PAH due to idiopathic pulmonary arterial hypertension (IPAH) or familial
 pulmonary arterial hypertension (FPAH).

 -  6-minute walk distance (6-MWD) between 100-450 meters at screening.

 -  On a stable dose of sildenafil, with or without bosentan.

 Exclusion Criteria:

 -  Any treatment for PAH with prostacyclins, prostacyclin analogues, endothelin-1
 antagonists, or phosphodiesterase-5 (PDE-5) inhibitors other than sildenafil within
 the past 12 weeks.

 -  Pulmonary hypertension due to conditions other than those stated in inclusion
 criteria.

 -  Additional PAH medications added within the past 12 weeks.